IMS Health has upped its count of “pharmerging” countries to 17 high-growth pharmaceutical markets. Previously, only seven markets qualified. According to IMS Health, these 17 countries represent $90 billion of increased pharmaceutical spending during 2009-13, collectively offering 48% of the growth in the market in 2013. China is the most significant opportunity of the 17, a market that is “in a league of its own,” in the words of the healthcare consultancy company. More details...

Stock Symbol: (NYSE: IMS)